Protection by design

MEVOX combines in-house expertise with world class partnerships in antigen design and disease. We leverage this translational expertise and cutting-edge vaccine innovation to bring established vaccines into the 21st century and address significant unmet needs.

Who is MEVOX ?

MEVOX brings vaccinology into the 21st century.  We translate cutting-edge molecular characterization, design and engineering into conformationally precise and optimized protein antigens.  These induce 10-100 times higher neutralising antibody levels than existing vaccines.  We embed this scientific excellence in partnerships with world leaders on our target diseases and antigen characterization and design.  Our goal is global health impact through protection by design.


Mike Watson and Guillaume Stewart-Jones
are the executives of Mevox ltd.

Mike Watson

Michael Watson

Guillaume Stewart-Jones

Chief Scientific Officer
Guillaume Stewart-Jones

and our investors

Our Values

Vaccine Architects Engineering
Protection by design

Contact Us